Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Timothy Dorius (NPI 1689961484)

Field	Value
Entity Type	Individual
Organization	Timothy Dorius
Address	8303 Dodge St Ste 250
City	Omaha
State	NE
ZIP	68114
Taxonomy	Internal Medicine Physician
NPI Enumerated	June 30, 2011

Payer Source	Total Paid
Medicare	$1M
Medicaid	$0

Key Findings

This provider’s Medicare billing is concentrated in infusion and oncology-related drug administration: the largest single code by revenue is J9271 (pembrolizumab) with $688K representing 68.6% of the provider’s Medicare revenue, and precomputed top-3 codes together account for 81.9% of total Medicare revenue. The code mix (J9271, J0897 denosumab, and J2506 pegfilgrastim) indicates an operational focus on high-cost oncology biologics and supportive oncology infusions rather than primarily office-based primary care visits.

Overall scale and payer mix are effectively single-payer: lifetime Medicare revenue is $1M while there is no Medicaid billing on file, so this provider operates with Medicare as the dominant — effectively sole — public-payer revenue source. Analysts should treat this profile as Medicare-dependent for public-program volume comparisons and network impact analysis.

Competitive standing on the top revenue driver is modest at the national level: J9271 volume ranks #614 of 1841 providers nationally (66th percentile), which the source characterizes as typical or unremarkable volume for the code. Despite generating the majority of this provider’s Medicare revenue, their national rank indicates they are not a dominant national supplier of pembrolizumab but rather a mid-level participant among infusion providers billing this drug.

There are specific codes where the provider is notably above typical national volume: 99214 (established outpatient E/M) ranks #22176 of 479517 providers nationally (95th percentile) and is labeled notably above typical national volume. This suggests the practice conducts a high volume of moderate-complexity established patient visits in addition to infusion services, supporting ongoing management of complex patients receiving biologic therapy.

Several supportive oncology and chemotherapy administration codes appear at typical volumes and collectively reinforce an infusion center model: J0897 denosumab ($65.9K, 6.6%), J2506 pegfilgrastim ($41.7K, 4.2%), 96413 chemotherapy infusion ($35.5K, 3.5%), and multiple add-on and infusion maintenance codes (96417, 96367, 96375) each show typical, unremarkable national percentile positions. The spread across initial infusions, add-on hours, and supportive medications indicates integrated chemotherapy administration capabilities rather than isolated drug dispensing.

Service mix includes both outpatient E/M and inpatient/observation care but at much lower revenue shares: codes for hospital initial and subsequent care (99223, 99232) and high-level new-patient visits (99205) are present but together represent small portions of revenue. This pattern is consistent with a practice that primarily bills for infused oncology drugs while maintaining clinic and hospital continuity for its treated patient population.

Tenure is long enough to establish local presence: the provider’s NPI was enumerated on 2011-06-30 (about 15 years ago), indicating sustained enrollment in Medicare and a potentially stable referral base and operational history for infusion services. Analysts should consider this when assessing continuity of care and historical revenue trends.

Revenue concentration risk is high due to dependence on a very small set of codes: with the top three Medicare codes accounting for 81.9% of Medicare revenue, changes in utilization or payer policy for these specific biologics or their administration could meaningfully affect the practice’s revenue. Payers and network planners evaluating contracting or utilization management should prioritize oversight of these high-share drug codes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

37 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	16,000	$40	$688K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	760	$90	$67.4K
J0897	Injection, denosumab, 1 mg	3,660	$20	$65.9K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	470	$90	$41.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	390	$90	$35.5K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	5,000	$10	$30K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	70	$160	$11.1K
96417	In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy…	190	$50	$9K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	70	$130	$8.8K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	350	$20	$7.4K

Showing 1–10 of 37

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 37 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Timothy Dorius — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

37 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	11	30	14,400	$40	$671.6K
J0897	54	200	2,040	$20	$62.7K
J2506	9	20	460	$90	$40.5K
J0885	1	10	3,180	$10	$19.2K
96413	16	80	60	$90	$18.2K
99214	155	3,210	110	$70	$14.9K
99232	661	1,390	80	$60	$8.6K
Q0138	2	10	16,830	$1	$8.2K
99213	2,281	3,220	90	$50	$7.9K
99215	253	920	40	$110	$7K

Showing 1–10 of 37

Related Providers

Other providers that share a Tax Identification Number (TIN) with Timothy Dorius, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Oneworld Community Health Centers, Inc.	NE	Federally Qualified Health Center (FQHC)	$0	$45.1M
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
Alegent Creighton Clinic	IA	Family Medicine Physician	$0	$9.6M
James Uyeki	TX	Medical Oncology Physician	$6.7M	$0
Brennen Cheek	TX	Radiation Oncology Physician	$5.9M	$0
Samer Renno	NE	Hematology & Oncology Physician	$3.2M	$0
Stefano Tarantolo	NE	Hematology & Oncology Physician	$3.2M	$0
Joel Lurie	TX	Nurse Practitioner	$2.8M	$0
Sreedevi Daggubati	TX	Hematology & Oncology Physician	$2.8M	$0
Robert Berryman	TX	Medical Oncology Physician	$2.7M	$0

Nearby Providers

Other providers in the same ZIP code as Timothy Dorius, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Children's Hospital & Medical Center	NE	Children's Hospital	$0	$89.8M
Children's Physicians	NE	Pediatrics Physician	$0	$39.4M
Nebraska Pediatric Practice, Inc	NE	Pediatrics Physician	$0	$29M
Physicians Clinic Inc	NE	Family Medicine Physician	$0	$20.5M
Nebraska Methodist Hospital	NE	General Acute Care Hospital	$0	$14.5M
Smiles 4 Kids PC	NE	General Practice Dentistry	$0	$11.5M
Children's Hospital	NE	Pediatric Emergency Medicine (Pediatrics) Physician	$0	$8.4M
Nebraska Methodist Hospital	NE	Emergency Medicine Physician	$0	$5.3M
Unmc College Of Dentistry	NE	Dentist	$0	$4.8M
Stones Worth Stepping, P.C.	NE	Occupational Therapist	$0	$4.7M

Timothy Dorius — Billing Profile & Reimbursement Data

Sign up for Timothy Dorius — Billing Profile & Reimbursement Data policy alerts

Timothy Dorius — Billing Profile & Reimbursement Data

Sign up for Timothy Dorius — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References